Nathalie Brandenberg is co-founder and co-CEO of SUN bioscience, an EPFL spin-off active in the industrial production of stem cell organoids for precision medicine. She holds a BSc/MSc/PhD in Bioengineering and Biotechnology from EPFL. She is currently developing a novel screening method for cystic fibrosis on human intestinal organoids for clinical precision medicine. She has experience in areas such as biofabrication, biomaterial development, microfluidics and developmental biology and has co-authored numerous publications in peer-reviewed journals. In 2016, Nathalie Brandenberg was named to the Forbes 30 Under 30 list in the Science and Healthcare category, along with her co-founder Sylke Hoehnel.